Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial

Oncogenic RET fusions occur in diverse cancers. Pralsetinib is a potent, selective inhibitor of RET receptor tyrosine kinase. ARROW (NCT03037385, ongoing) was designed to evaluate pralsetinib efficacy and safety in patients with advanced RET-altered solid tumors. Twenty-nine patients with 12 differe...

Descripción completa

Detalles Bibliográficos
Autores principales: Subbiah, Vivek, Cassier, Philippe A., Siena, Salvatore, Garralda, Elena, Paz-Ares, Luis, Garrido, Pilar, Nadal, Ernest, Vuky, Jacqueline, Lopes, Gilberto, Kalemkerian, Gregory P., Bowles, Daniel W., Seetharam, Mahesh, Chang, Jianhua, Zhang, Hui, Green, Jennifer, Zalutskaya, Alena, Schuler, Martin, Fan, Yun, Curigliano, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9388374/
https://www.ncbi.nlm.nih.gov/pubmed/35962206
http://dx.doi.org/10.1038/s41591-022-01931-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9388374/
https://www.ncbi.nlm.nih.gov/pubmed/35962206
http://dx.doi.org/10.1038/s41591-022-01931-y

Ejemplares similares